Asensus Surgical gains FDA approval for articulating instruments
Asensus Surgical (formerly TransEnterix) has received FDA 510(k) clearance for 5mm diameter articulating instruments, adding to the Senhance Surgical System technology platform. Articulating instruments offer better access to difficult-to-reach areas of the anatomy by providing two additional degrees of freedom. These instruments have previously received CE Mark for use in the European Union.
“Bringing the benefits of 5mm articulating instruments to the Senhance Surgical System in the US will widen the clinical utility and value of our platform,” said Anthony Fernando, Asensus Surgical President and CEO. “Combining articulation and haptics with augmented intelligence is a very promising development for Performance-Guided Surgery."
Asensus Surgical's claims its technology platform, the Senhance Surgical System, is the first of its kind digital laparoscopic platform that leverages augmented intelligence to provide unmatched performance and patient outcomes through machine learning. According to the company, Senhance goes beyond the typical surgical robotic systems, providing surgical assurance through haptic feedback, eye-tracking camera control and 3D visualisation, and is the first platform to offer 3mm instruments. Articulating instruments are the latest addition to the Senhance Surgical System in the United States, further enhancing surgical performance with robotic precision.